All In Biotech

Drug Trial Radar · NCT07075718

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Jun 12, 2025

Primary completion

Mar 2028

Study completion Mar 2032

Sponsor

Lead sponsor
Glaukos CorporationIndustry
Sponsor type
Industry
First posted
Jul 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Conditions

  • Glaucoma

Interventions

  • Gen 2 Travoprost Intracameral ImplantDrug

    travoprost

  • Timolol eye drops 0.5%Drug

    timolol 0.5%

  • Sham ProcedureProcedure

    sham implant administration

  • Placebo eye dropsOther

    artificial tears

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraocular pressure (IOP)Time frame: 3 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Glaukos Investigative Site

    Grand Junction, Colorado · Recruiting

  • Glaukos Investigative Site

    Oklahoma City, Oklahoma · Recruiting

  • Glaukos Clinical Site

    El Paso, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.